Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19
Sponsor: The Cleveland Clinic
Summary
Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course of COVID-19 in patients with ALD and test whether HMB can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.
Official title: Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19
Key Details
Gender
All
Age Range
21 Years - Any
Study Type
INTERVENTIONAL
Enrollment
48
Start Date
2021-04-01
Completion Date
2026-12-31
Last Updated
2025-11-25
Healthy Volunteers
No
Interventions
β-hydroxy β-methyl butyrate (HMB) enriched amino acid
β-hydroxy β-methyl butyrate (HMB) is a non-nitrogenous leucine metabolite with anabolic properties.
Balanced amino acid
Balanced amino acid is the balanced mixture of the various essential amino acids.
Locations (1)
Cleveland Clinic Foundation
Cleveland, Ohio, United States